GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2013

Evotec, Dana-Farber Partner on Cancer Epigenetics Drug Development

  • Investigators at the Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science and Evotec are working together to discover and commercialize cancer treatments based on epigenetic drug mechanisms, the organizations announced today.

    Together, Dana-Farber and Evotec hope to validate emerging epigenetic targets for oncology indications and demonstrate the drugability of the selected target families, they said. Financial terms of the agreement were not disclosed.

    “This pioneering partnership provides a unique opportunity to combine Evotec's drug discovery capabilities with Belfer Institute for Applied Cancer Science and Dana-Farber Cancer Institute's expertise in oncology disease biology to accelerate the development of new medicines for patients,” Jessie English, head of research at the Belfer Insitute, said in a statement.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?